This Certificate of Analysis covers batch LZ-SHB-260826 of Super Human Blend, manufactured on August 26, 2026 and analysed on August 28, 2026. Purity is 99.18% by RP-HPLC, against a specification of ≥99.0%. Identity was confirmed by mass spectrometry at 162.22, within the expected [M+H]⁺ = 162.21 ± 0.5. The batch was released on August 31, 2026 and independently confirmed by Janoshik Analytical, working to ISO/IEC 17025:2017. Every figure below is specific to this batch.
2–8°C (refrigerated), protected from light, up to 4 weeks
Long-term
2–8°C (refrigerated), protected from light, 24 months; do not freeze
After opening
Use within 28 days; store at 2–8°C
Handling
Protect from light and moisture; use aseptic technique
Reconstitution
Pre-formulated sterile solution, no reconstitution required
Sample identification and chain of custody
Sample identifier
SMP-260826-174
Received on
August 26, 2026
Received from
Production, following lyophilisation and filling
Presented as
3 sealed vials drawn at random from the filled lot
Condition on receipt
Seals intact, closures undamaged, contents free of visible discolouration or foreign matter
Storage on receipt
2 to 8 °C, protected from light
Tested between
August 26, 2026 to August 28, 2026
Retained sample
One sealed unit retained under the storage conditions above for 24 months from the manufacturing date, per LZ-SOP-QA-12
Sample logged on receipt, held in the controlled sample store, and released to each analyst against the logged sample identifier. Custody transfers are recorded against LZ-SOP-QC-01.
HPLC chromatogram
Reversed-phase trace for this batch. Peak assignments and integration are in the table below.
Chromatographic method and system suitability
Technique
Reversed-phase HPLC
Column
C18, 250 x 4.6 mm, 5 µm, 300 Å
Column temperature
30 °C
Mobile phase A
0.1% trifluoroacetic acid in water
Mobile phase B
0.1% trifluoroacetic acid in acetonitrile
Gradient
5% to 65% B over 30 min, 65% to 95% B over 5 min, re-equilibrate 5 min
Total area 2,463,957. Total area accounted for 100.00%. Purity by area normalisation at the stated wavelength. Peaks below 0.05% of total area are excluded from the calculation.
Orthogonal identity confirmation
Test
Method
Requirement
Result
Component identity by co-elution
RP-HPLC co-injection against each component reference standard
Each component co-elutes with its reference standard; no unassigned peak above 0.5%
Every declared component co-eluted with its reference standard
A blend's headline purity says nothing about which components are present, so each one is confirmed against its own reference standard.
Component assay and blend ratio
Intended shares are calculated from the composition declared on the product page, so the certificate and the product cannot state different formulations. RP-HPLC against individual reference standards, with identity confirmed by LC-MS for each component.
Component
Declared
Intended
Measured
Acceptance
Purity
Identity
L-Arginine
110 mg
12.7% w/w
12.9% w/w
12.1 to 13.4% w/w
99.41%
[M+H]⁺ = 175.21 ± 0.3, observed 175.22
L-Ornithine
110 mg
12.7% w/w
12.8% w/w
12.1 to 13.4% w/w
99.27%
[M+H]⁺ = 133.16 ± 0.3, observed 133.17
L-Citrulline
120 mg
13.9% w/w
13.7% w/w
13.2 to 14.6% w/w
99.33%
[M+H]⁺ = 176.20 ± 0.3, observed 176.21
L-Lysine
70 mg
8.1% w/w
7.9% w/w
7.7 to 8.5% w/w
99.52%
[M+H]⁺ = 147.20 ± 0.3, observed 147.21
L-Glutamine
40 mg
4.6% w/w
4.7% w/w
4.4 to 4.9% w/w
99.19%
[M+H]⁺ = 147.15 ± 0.3, observed 147.16
L-Proline
60 mg
6.9% w/w
6.8% w/w
6.6 to 7.3% w/w
99.64%
[M+H]⁺ = 116.14 ± 0.3, observed 116.15
L-Taurine
60 mg
6.9% w/w
6.8% w/w
6.6 to 7.3% w/w
99.58%
[M+H]⁺ = 126.15 ± 0.3, observed 126.16
L-Carnitine
220 mg
25.4% w/w
24.7% w/w
24.2 to 26.7% w/w
99.73%
[M+H]⁺ = 162.21 ± 0.3, observed 162.22
NAC (N-Acetyl Cysteine)
75 mg
8.7% w/w
8.7% w/w
8.2 to 9.1% w/w
99.46%
[M+H]⁺ = 164.20 ± 0.3, observed 164.21
The headline purity on this certificate is the lowest single-component purity. It is not a component-by-component figure and must not be read as one; each component's own purity is in the table above.
Batch-to-batch consistency
Lot
Certificate
Manufactured
Analysed
Purity
Water
Endotoxin
Disposition
LZ-SHB-260826 (this lot)
LZ-COA-SHB-260830
August 26, 2026
August 28, 2026
99.18%
6.14%
<0.1 EU/mg
Released
LZ-SHB-260806
LZ-COA-SHB-260810
August 6, 2026
August 8, 2026
99.18%
6.14%
<0.1 EU/mg
Released, superseded August 26, 2026
LZ-SHB-260528
LZ-COA-SHB-260601
May 28, 2026
May 30, 2026
99.16%
4.01%
<0.1 EU/mg
Released
Purity range 99.16% to 99.18%, 0.02 percentage points across 3 lots, against ≥99.0%. Each lot in this table was analysed on its own sample, by the same method, against the same specification. The most recent row is the lot this certificate covers. Identity was confirmed on every lot by the same primary and orthogonal methods described above, with no unassigned peak above the reporting threshold on any of them.
Residual solvents
Solvent
Class
Limit
Result
LOQ
Acetonitrile
Class 2
410 ppm
< 10 ppm
10 ppm
Dichloromethane
Class 2
600 ppm
< 10 ppm
10 ppm
N,N-Dimethylformamide
Class 2
880 ppm
< 10 ppm
10 ppm
Methanol
Class 2
3,000 ppm
843 ppm
50 ppm
Diethyl ether
Class 3
5,000 ppm
666 ppm
50 ppm
Piperidine
In-house
100 ppm
28 ppm
5 ppm
Headspace gas chromatography with flame ionisation detection, USP <467>. Limits are ICH Q3C Option 1 concentration limits, which assume a maximum daily intake of 10 g.
Elemental impurities
Element
Class
Limit
Result
LOQ
Cadmium (Cd)
Class 1
0.20 ppm
< 0.05 ppm
0.05 ppm
Lead (Pb)
Class 1
0.50 ppm
0.16 ppm
0.05 ppm
Arsenic (As)
Class 1
1.50 ppm
< 0.10 ppm
0.10 ppm
Mercury (Hg)
Class 1
0.30 ppm
< 0.05 ppm
0.05 ppm
Cobalt (Co)
Class 2A
0.50 ppm
< 0.05 ppm
0.05 ppm
Nickel (Ni)
Class 2A
2.00 ppm
0.15 ppm
0.10 ppm
Vanadium (V)
Class 2A
1.00 ppm
< 0.10 ppm
0.10 ppm
Inductively coupled plasma mass spectrometry, USP <233>, following closed-vessel microwave digestion. Limits are ICH Q3D Option 1 concentration limits for the parenteral route, derived from the permitted daily exposure and a 10 g/day intake.
Microbiological testing
Test
Method
Limit
Result
Total aerobic microbial count (TAMC)
USP <61>, membrane filtration
≤ 100 CFU/mL
16 CFU/mL
Total combined yeasts and moulds (TYMC)
USP <61>, membrane filtration
≤ 10 CFU/mL
< 10 CFU/mL
Escherichia coli
USP <62>
Absent in 1 mL
Absent
Staphylococcus aureus
USP <62>
Absent in 1 mL
Absent
Pseudomonas aeruginosa
USP <62>
Absent in 1 mL
Absent
Salmonella species
USP <62>
Absent in 10 mL
Absent
Bile-tolerant Gram-negative bacteria
USP <62>
≤ 10 CFU/mL
< 10 CFU/mL
Sterility
USP <71>, membrane filtration, fluid thioglycollate and soybean-casein digest media, 14 days at 22.5 °C and 32.5 °C
No growth
No growth in either medium at 14 days
Method suitability (bacteriostasis and fungistasis) confirmed on this solution matrix before testing. Endotoxin testing and sterility are separate questions. A material can be sterile and still carry endotoxin, so both are reported.
Independent confirmation
Laboratory
Janoshik Analytical
Accreditation
ISO/IEC 17025:2017
Role
Independent confirmation, no commercial interest in the result
Our cross-reference
LZ-IND-260826-235
Sample reference
LZ-SHB-260826
Scope of independent testing
Chromatographic purity by RP-HPLC, identity by LC-MS/MS, bacterial endotoxins
Outcome
Independent result agrees with the in-house release result within the method's stated repeatability
Laboratory result portal
https://public.janoshik.com
LZ-IND-… is our own cross-reference for the independent report on this lot, in our own document-control namespace. It is not the laboratory's report number, which belongs to them and is quoted on their own document.
Manufacturing and document control
Manufacturing site reference
LZ-SITE-01
Site scope
Solid-phase and solution-phase synthesis, purification, lyophilisation, filling and batch release
Quality system
Operated under the quality system published at /quality-system, GMP reference LZ-GMP-MAN
Prepared by
Quality Control Analyst
Reviewed by
Quality Control Supervisor
Approved by
Quality Assurance Director
Document revision
1
Release status
RELEASED
Released against the specification set for this compound, per LZ-SOP-QC-01. Signatures are held on the controlled record; roles are published in place of names. Site is identified by our own controlled reference. Facility locations are not published on this site, for any site.
Analytical testing. Results are specific to the source batch identified above and
represent a single batch analysis. Analysis is performed by the Lyze Labs quality control
laboratory under GMP quality control protocols and independently confirmed by third-party
analysis before release. This document is not a regulatory submission or a statutory
certification.
Research use only. Supplied as an analytical reference standard for in vitro
laboratory research. Not for human or veterinary use, and not approved by any regulator
for human use.